Search results
Red Light Holland Announces Completion of Full Psilocybin Extraction Report with PharmAla
Benzinga· 8 hours agoMDMA MDXXF ("PharmAla"). This significant achievement marks the successful extraction and creation of a high-quality, concentrated psilocybin extract at PharmAla's partner lab facilities Chiral ...
Bio-Sourcing and Afrigen Biologics partner on biomanufacturing platform
Pharmaceutical Technology via Yahoo Finance· 2 days agoBelgian biotech, Bio-Sourcing, and Cape Town based company, Afrigen Biologics, have signed a...
Even during biotech down cycle, nearly two dozen Bay Area companies flock to major convention - San...
The Business Journals· 1 day agoWhen Moonwalk Biosciences Inc. CEO Alex Aravanis started his presentation at the BIO convention in...
Vita Biotech Retains CBIH Services for Clinical Studies
Digital Journal· 2 days agoCBIH and Vita Biotech look forward to potentially bolster the credibility of our research among leading pharmaceutical companies, paving the way as pioneers ...
Pharma’s $1 Trillion ‘Firepower’ Hangs Over Biotech Stocks in Limbo
Bloomberg via Yahoo Finance· 4 days ago(Bloomberg) -- A flurry of deals at the start of the year sparked optimism for a biotech stock...
Goldman Sachs says buy this biotech stock with more than 60% upside
CNBC· 2 days agoIt's time for investors to buy the dip on Jazz Pharmaceuticals , according to Goldman Sachs. The...
US lawmakers ask FBI for briefing on GenScript Biotech's links to China
Reuters· 6 days agoIn a letter dated May 30 to the FBI and the U.S. office of the director of national intelligence,...
Why Nutriband (NASDAQ: NTRB) Is 'One to Watch'
Digital Journal· 4 days agoNutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse deterrent fentanyl ...
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider | The Motley Fool
The Motley Fool· 4 days agoIn biotech, disruptive companies could be those with unique technology platforms with uncommon capabilities, or those with programs for medicines that could be unusually effective ...
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You? | The Motley Fool
The Motley Fool· 3 days agoVia her ARK Innovation ETF (ARKK 1.47%), portfolio manager Cathie Wood makes a lot of biotech bets,...
